Navigation Links
GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
Date:9/9/2009

NEW YORK, Sept. 9 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), today released important information about its anti-cancer drug development strategy and its unique niche in the drug development industry.

The Company is aggressively acquiring patents involving the latest generation of biotherapeutic technologies that can cure cancer without any side effects.

With a focus on prostate and breast cancers, GENova has acquired a unique class of drugs that utilize stem cell technology to identify, target, and destroy the very originator stem cells that give rise to cancers. These bio-engineered drugs can seek out cancers right at the source, and destroy them whilst leaving healthy tissues intact.

The Company has already filed patents for these drug targets, and has identified similar ones for acquisition. Researchers in academic labs have expressed confidence that this novel approach to treating cancer is the way of the future, and will render current painful treatments obsolete.

John Savin, VP for GENova, explained the Company's unique strategy for penetrating the lucrative drug development industry: "We occupy a strategic point in the drug development and supply chain, as the intermediary between research institutions and the Big Pharmaceutical companies. Our strategy is one of global outsourcing, international collaboration, using the FDA fast track to accelerate drug development, and then early exit to cash-rich and technology-hungry Big Pharma."

Savin said that if GENova's current IP is developed successfully, he estimates that the Company could expect up to $100 Million in milestone payments during clinical trials, and up to $400 Million per annum in the years following commercialization. His estimates are based on evaluations of other successful drug targets in the industry.

Big Pharma presently has $215 Billion to spend on licensing of new drugs, and is eager to feed the
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
2. Genova files patent for new prostate cancer treatment
3. GENova names Dr. John Savin as Vice President
4. GENova names Aaron Whiteman as CEO
5. Karmanos Chief Cancer Surveillance Researcher Discusses Study on Decreased Cancer Mortality Rates
6. Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates
7. The Caryl Ehrlich Program Discusses Food Addiction on HealthyPlace.com
8. Natural Healers Discusses How Personal Trainer Certification May Be Changing in Some States
9. Natural Healers Discusses How Alternative Medicine Careers Provide a Little 'Wellness' in a Tough Economy
10. Cord Blood America CEO Discusses New State-of-the-Art State Laboratory in Fox News Television Interview
11. All Nursing Schools Discusses Obama's Health Care Reform and Nursing Career Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... to 70% of Parkinson,s disease (PD) patients experience ... life. Some patients have disturbed sleep/wake patterns such ... other patients may be subject to sudden and ... patients may exhibit REM-sleep behavior disorder (RBD), characterized ... before motor symptoms appear. A review in the ...
(Date:7/10/2014)... Rutgers University-Newark says the human brain operates much the ... that could provide a better understanding of schizophrenia, bipolar ... an estimated 13.6 million Americans. , In newly published ... an assistant professor at the Center for Molecular and ... a person at rest is basically the same as ...
(Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:Working to loosen the grip of severe mental illness 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3
... the 150 million customer mark, an intense debate continues ... once led by nonprofits. "Microfinance Meets the Market," just ... advances the debate, presenting new research from Jonathan Morduch ... University,s Wagner Graduate School of Public Service, and Robert ...
... better balance in a slippery situation , , FRIDAY, Feb. ... where the footing is unstable helped train them to ... says a University of Illinois at Chicago study. ... develops fall prevention strategies that can be used in ...
... Ill., Feb. 20 Abbott ( NYSE: ABT ) ... from the European Commission for its acquisition of Advanced ... the outstanding shares of common stock of AMO. ... the condition to the tender offer related to European ...
... CHADDS FORD, Pa. and DANBURY, Conn., Feb. 20 ... Pharmaceuticals (Nasdaq: PPCO ) announced today that ... LLC regarding the production and sale of generic formulations ... Endo and Penwest have agreed to dismiss their ...
... FOR RELEASE UNTIL 4:00 P.M., ET, FRIDAY, FEBRUARY 20, ... Bride, (651) 695-2795, jmacbride@aan.com , Young Smokers Increase ... start smoking before age 17 may increase their risk ... released today that will be presented at the American ...
... Treatment targeting damaged brain areas did not bring significant ... (HealthDay News) -- An experimental laser treatment of ... stroke patients, researchers report. , The trial was the ... stroke. , In the trial, the researchers at the ...
Cached Medicine News:Health News:Research reveals best paths for success as microfinance sector grows 2Health News:Adapting Gait May Help Elderly Avoid Falls 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 2Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 4Health News:Laser Therapy Disappoints in Stroke Trial 2
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ... agreement with Hitachi Koki of Japan ... North America . NuAire will utilize its network ... and Canada to offer assistance in application ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014   Evidera ... healthcare industry, announced that the Center for Drug Evaluation ... released its first draft qualification guidance document for a ... of Exacerbations of Chronic Pulmonary Disease Tool [EXACT] for ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Inquire...
Guaranteed leak-proof , Teflon coating is impervious to corrosive materials , Shock-resistant , NBS tolerances of accuracy , Thermometers are 225 mm long with an immersion length of 35 mm ...
... efficient refrigerator on the market today. The ... unit. The contoured drain channels away moisture ... walls are coated with a tough, baked-on ... door is reversible. The interior of the ...
Medicine Products: